The association of circulating endocannabinoids with neuroimaging and blood biomarkers of neuro-injury

Keyphrases

• Hippocampal Volume 100%
• Imaging Biomarkers 100%
• Blood Biomarkers 100%
• Endogenous Cannabinoids 100%
• Alzheimer's Disease 66%
• Potential Confounders 66%
• Neurodegeneration 66%
• Effect Modification 66%
• Alzheime's Disease 66%
• Dementia 33%
• Diverse Populations 33%
• Gray Matter Volume 33%
• Sex Differences 33%
• Linear Regression Model 33%
• Liquid Chromatography-high Resolution Mass Spectrometry (LC-HRMS) 33%
• Cognitively Healthy 33%
• Total tau 33%
• Older Participants 33%
• Prospective Design 33%
• Early Markers 33%
• Neurodegenerative Diseases 33%
• White Matter Hyperintensity Volume 33%
• Brain MRI 33%
• Brain Volume 33%
• Brain Aging 33%
• Fatty Acids 33%
• Postmenopausal Women 33%
• UCHL1 33%
• Neurofilament Light (NF-L) 33%
• Accelerated Brain Aging 33%
• Framingham Heart Study Offspring Cohort 33%
• N-acyl Amino Acids 33%
• Glial Fibrillary Acidic Protein 33%
• Sex-specific Association 33%
• Linoleoylethanolamide 33%
• Fatty Acid Ethanolamides 33%
• Acid Compounds 33%
• Correction for multiple Comparisons 33%

Neuroscience

• Neurodegeneration 100%
• Endocannabinoid 100%
• Alzheimer's Disease 100%
• Fatty Acids 100%
• Biological Marker 100%
• Mass Spectrometry 50%
• Hydrolase 50%
• Magnetic Resonance Imaging of Brain 50%
• Neurodegenerative Disorder 50%
• N Acylamino Acid 50%
• Protein C 50%
• Neurofilament 50%
• Ubiquitin C 50%
• Glial Fibrillary Acidic Protein 50%
• C-Terminus 50%
• Gray Matter Volume 50%
• Chromatography 50%
• Multiple Comparison 50%